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Abstract 
 
In this study we evaluated the effects of selective Na+/Ca2+ exchanger (NCX) inhibition by 
ORM-10103 on the [Ca2+]i transient (CaT), action potential (AP), and cell viability in isolated 
canine ventricular cardiomyocytes exposed to a simulated ischemia/reperfusion protocol 
performed either alone (modeling moderate low-flow ischemia) or with simultaneous 
strophantidine challenge (modeling more severe low-flow ischemia). CaTs were monitored 
using a Ca2+-sensitive fluorescent dye, APs were recorded by intracellular microelectrodes, 
and anaerobic shifts in cellular metabolism were verified via monitoring native NADH 
fluorescence. Simulated ischemia increased the NADH fluorescence, reduced the amplitudes 
of the AP and CaT and induced membrane depolarization. APs moderately shortened, CaTs 
prolonged. Diastolic [Ca2+]i ([Ca2+]iD) level increased significantly during ischemia and 
further elevated following strophantidine application. Reperfusion normalized the NADH 
level, the amplitude of the AP and duration of the [Ca2+]i transient, but only partially restored 
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action potential triangulation and the amplitude of the CaT. [Ca2+]iD decreased in untreated, 
but further increased in strophantidine-treated cells. 10 μM ORM-10103 significantly reduced 
the ischemic [Ca2+]i raise in both untreated and strophantidine-treated cells. During 
reperfusion ORM-10103 decreased [Ca2+]i and eliminated its diastolic elevation in untreated 
and strophantidine-treated cardiomyocytes. Following the application of ORM-10103 the 
detrimental effect of ischemia/reperfusion on cell viability and the reperfusion-induced 
increase in AP and CaT variabilities were substantially reduced, but ischemia-induced shifts 
in AP morphology were barely influenced. In conclusion, selective NCX inhibition by ORM-
10103 is highly effective against ischemia/reperfusion induced pathologic alterations in 
[Ca2+]i homeostasis, however, it fails to normalize untoward arrhythmogenic changes in AP 
morphology. 
Key words: ischemia/reperfusion, [Ca2+]i homeostasis, [Ca2+]i transient, action potential, 
NCX inhibitors, ORM-10103
 
1. Introduction 
Cardiac Na+/Ca2+ exchanger has a pivotal role in removal of the excess Ca2+ (forward 
transport mode) entering mainly via L-type Ca2+ channels during the AP, however it may also 
contribute to Ca2+ entry (reverse transport mode). Therefore, its balanced activity is essential 
in maintaining cardiac [Ca2+]i homeostasis and any abnormal change in its transport activity 
may severely impair the contractile function and the electrical activity of the beating heart.   
During hypoxia the raise in [Na+]i shifts the NCX into its reverse transport mode. The 
reduction in [K+]i depolarizes the sarcolemma (Baczko et al., 2003; Tanaka et al., 2002), 
further facilitating reverse mode NCX activity and leads to gradual [Ca2+]i accumulation. 
During the early phase of ischemia the major source of the [Ca2+]i increase is the leaky SR 
(Zucchi and Ronca-Testoni, 1997), while during the late phase, [Ca2+]i accumulation via NCX 
is accelerated (Bourdillon and Poole-Wilson, 1981; Haigney et al., 1992). During reperfusion 
the secondary [Na+]i raise further activates the already high reverse mode transport, 
generating [Ca2+]i overload and subsequently increased SR Ca2+ content. These alterations 
often lead to abnormal membrane potential changes (Volders et al., 2000) enhanced 
probability of diastolic Ca2+ releases (Diaz et al., 1997), enhanced arrhythmia propensity 
(early and delayed afterdepolarizations) and cellular injury (Talukder et al., 2009). During 
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incomplete (low-flow) ischemia/reperfusion the changes in [Na+]i and [Ca2+]i homeostasis are 
less dramatic (Wei et al., 2007).
Up to present benzyloxyphenyl derivatives KB-R7943 and SEA0400 were considered 
as the best NCX inhibitors. In isolated rat cardiomyocytes exposed to simulated ischemia KB-
R7943 reduced the [Ca2+]i overload and delayed the onset of the contracture (Ladilov et al., 
1999). The raise in [Ca2+]i, induced by the removal of extracellular Na+, was blocked by 90% 
in the presence of KB-R7943 (Tokuno et al., 2000). In reoxygenated rat cardiomyocytes 
hypercontracture and [Ca2+]i oscillations were significantly reduced in the presence of KB-
R7943 (Schafer et al., 2001). Both SEA0400 and KB-R7943 inhibited the Na+-dependent 
Ca2+ uptake in rat cardiomyocytes. Similar, positive effects of NCX inhibition were reported 
from isolated guinea pig papillary muscles and rat hearts (Anderson, 2002; Schafer et al., 
2001; Wang et al., 2007). NCX inhibitors were shown to attenuate myocardial reperfusion 
injury using in vivo experimental models (Takahashi et al., 2003). Under normal conditions or 
during ischemia 1 μM SEA0400 had no apparent effect on AP configuration, but improved 
the recovery of action potentials after reperfusion (Acsai et al., 2007). 
Previous data (Inserte et al., 2002; MacDonald and Howlett, 2008; Wei et al., 2007) 
suggest that inhibition of the reverse mode NCX activity during ischemia/reperfusion exert 
effective cardioprotection by reducing [Ca2+]i overload and improving myocardial recovery 
during reperfusion. However, the inhibitors used in these studies were not fully selective 
(Birinyi et al., 2005), consequently the overall effect of NCX inhibition could not be 
quantitatively analyzed. Therefore, the aim of the present study was to evaluate the 
cardioprotective effect of a novel, selective NCX inhibitor, ORM-10103 (Jost et al.; 2013) in 
isolated canine ventricular cardiomyocytes in conditions of simulated ischemia/reperfusion. 
This aim was accomplished by analyzing the primary, simulated ischemia/reperfusion 
induced shifts in characteristic variables on the CaT and AP and evaluating the modulatory 
effects of selective, partial NCX inhibition on these shifts. Supplementary experiments were 
also performed in order to directly estimate and compare the survival rate during ischemia 
and reperfusion of untreated and ORM-10103 treated cardiomyocytes.
2. Materials and methods 
All animal experiments were carried out in compliance with the Guide for the Care 
and Use of Laboratory Animals (USA NIH publication NO 86-23, revised 1996) and 
conformed to Directive 2010/63/EU of the European Parliament. Furthermore, all 
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experimental protocols were approved by the Ethical Committee for Protection of Animals in 
Research of the University of Szeged, Hungary (permit No. I-74-9/2009).  
2.1.   Isolation of canine left ventricular cardiomyocytes 
Canine ventricular cardiomyocytes were isolated from adult mongrel dogs of either 
sex weighing 10 to 20 kg. Following sedation (xylazine, 1 mg/kg, i.v.) the animals were 
anaesthetized with 30 mg/kg thiopental and anticoagulated with sodium-heparin. The proper 
depth of anesthesia was carefully tested with pupilla and pain reflexes. Following right lateral 
thoracotomy the heart was quickly removed and immediately rinsed in oxygenated modified 
Locke's solution containing (in mM): Na+ 140, K+ 4, Ca2+ 1.0, Mg2+ 1, Cl- 126, HCO3- 25 and 
glucose 11. The pH of the solution, bubbled with 95% O2 and 5% CO2 at 37 °C, ranged from 
7.35 to 7.45. Excised left ventricular segments were perfused at 37 °C through the anterior 
descending coronary artery using a gravity flow Langendorff apparatus. First, to remove the 
blood the heart was washed for 5 min with isolation solution containing 1 mM Ca2+, than the 
perfusate was switched to a Ca2+-free solution containing (in mM) 135 NaCl, 4.7 KCl, 1.2 
KH2PO4, 1.2 MgSO4, 10 HEPES, 10 glucose, 20 taurine, 4.4 NaHCO3, and 5 Na-Pyruvate 
(pH 7.2 with NaOH). 10 min later, 75 M CaCl2 and 150 U/ml collagenase (Worthington 
Type II), and 15 min later 0.35 U/ml protease (Sigma Type XIV) was added to the perfusate. 
Cell dissociation lasted for 30-40 min. At the end of this isolation process the tissue was 
minced and gently agitated. The myocytes were harvested and stored in the isolation solution 
containing 1 mM Ca2+ at room temperature for the same day or at 4 °C for next day 
recordings. Following restoration of the external [Ca2+] at least 60% of the cardiomyocytes 
were rod-shaped showing clear striation. During measurements the cells were perfused with 
Tyrode solution. The Tyrode solution contained (in mM): 144 NaCl, 0.4 NaH2PO4, 4 KCl, 
0.53 MgSO4, 1.8 CaCl2, 5.5 glucose and 5 HEPES. The pH was set to 7.4 with NaOH. All 
measurements were performed at 37 °C. 
2.2. Determination of cell viability 
Freshly isolated, unloaded cardiomyocytes, subjected to the ischemia/reperfusion 
protocol were visually assessed, classified and counted in randomly selected microscopic 
fields (Olympus IX 71 inverted fluorescence microscope; 20x objective). A representative, 
circular region of the microscopic field (region of interest; ROI), containing predominantly 
contracting cells, was used for analysis. Still images of the ROI were periodically captured by 
an Olympus digital photo camera (C-7070). In order to safely distinguish living and dead 
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cells, instead of using vital dyes, we followed another, similarly effective classification, 
utilizing characteristic morphological variables, i.e. the shape and visibility of striation of the 
cells (Maddaford et al., 1999). Cardiomyocytes in the ROI were divided into two classes: 
Class A: cells with normal (not significantly shortened) shape, intact border and visible 
striation; Class B: cells dead or at the verge of death, in severe contracture, parallel striation 
cannot be observed. The cells were stimulated (1 Hz) throughout the experiment. The number 
of surviving and dead cells was determined several times (at 0th,1.5th,3rd, 4 th,10 th,15 th,23 th,24 
th,26 th,30 th,32nd minutes) during the ischemia/reperfusion protocol. 
2.3. Validation of the level of simulated ischemia via NADH measurements  
Parallel to the shift from aerobic to anaerobic metabolism a substantial fraction of the 
intramitochondrial NAD+ content is gradually reduced. Since only the reduced form, NADH 
is fluorescent, a raise in [NADH]m is considered as a direct indicator of ischemia. In this set of 
experiments NADH was excited at 360nm, while the native cellular fluorescence was 
monitored at 450nm. The relative magnitude of the momentary fluorescent shift compared to 
the maximal raise achieved following the application of 10 mM NaCN has been used to 
characterize the level of ischemia. Therefore, cardiomyocytes were stimulated at 1 Hz and the 
simulated ischemia/reperfusion protocol (i.e. 3-5 min normoxic control, 20 min simulated 
ischemia and 10 min reperfusion – see details below) was used. At the end of the protocol the 
cells were exposed to 10 mM cyanide, which quickly induced maximal NAD+ reduction. 
2.4. Monitoring [Ca2+]i transients in single ventricular cardiomyocytes 
[Ca2+]i transients were monitored using a Ca2+-sensitive fluorescent dye, Fluo 4. 
Isolated cardiomyocytes were loaded with 6 μM Fluo 4-AM (AM is the membrane permeable 
acetoxymethyl ester conjugated form of the dye) for 15 minutes at room temperature in dark. 
Loaded cells were mounted in a low volume imaging chamber (RC47FSLP, Warner 
Instruments) and field-stimulated at a rate of 1 Hz, while continuously superfused with 
normal (during control and reperfusion periods) or “simulated ischemic” Tyrode solution. 
Fluorescence measurements were performed on the stage of an Olympus IX 71 inverted 
fluorescence microscope. The dye was excited at 480 nm and the emitted fluorescence was 
detected at 535 nm. Optical signals were sampled at 1 kHz and recorded by a photon counting 
photomultiplier module (Hamamatsu, model H7828). Data acquisition and analysis were 
performed using a CAIRN Optoscan System. Alterations in [Ca2+]i were characterized by the 
corresponding changes in background corrected fluorescence normalized to the control state 
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(F/F0).  Amplitudes of the [Ca2+]i transients were calculated as differences between systolic 
and diastolic values. Diastolic [Ca2+]i  levels were determined immediately before the onset of 
the stimulus. Systolic [Ca2+]i was determined at the peak of the corresponding transient. 
[Ca2+]i changes were expressed as fluorescence measured over basal unstimulated 
fluorescence (F/F0). Background fluorescence levels were recorded for a few times during 
each experiment and were used to correct raw fluorescence data. 
2.5. Recording of single cell action potentials 
Single cell APs were recorded using conventional sharp microelectrodes. Selected 
cardiomyocytes were impaled with high-resistance (20-40 M) electrodes filled with 3 M 
KCl. APs were recorded with an Axoclamp 900A amplifier (Axon Instruments) and were 
analyzed using the Clampfit 10.0 software (Molecular Devices Corporation). Action potential 
parameters, like amplitude, plateau level, duration (both APD25 and APD90) and triangulation 
(APD90-APD25) of the AP, and the resting membrane potential were determined. 
2.6. Introducing simulated ischemia 
As in similar studies, simulated ischemia was introduced using a low pH, low pO2, 
high K+, glucose free, high lactate perfusion solution (composition (in mM): 123 NaCl, 6 
NaHCO3, 0.9 NaH2PO4, 8 KCl, 0.5 MgSO4, 2.5 CaCl2 and 20 lactate) (Louch et al., 2002).
The cells were first perfused with normal Tyrode solution (normoxia: 3 min), then with 
simulated ischemic solution (ischemia: 20 min), and finally again with normal Tyrode 
solution (reperfusion: 10 min). During the ischemic period an oxygen-free gas combination 
(95% N2 + 5% CO2) was layered over the solution. Each cell was exposed to the 
ischemia/reperfusion cycle only once. The oxygen level in the ischemic solution was 
decreased to a very low level by heavily gassing the solution with the anoxic gas mixture. The 
pO2 level in the solution was periodically checked using a clinical blood gas analyzer 
(Radiometer ABL 505). The pO2 level was approximately 180 mmHg in normal Tyrode. This 
rapidly declined to about 32 mmHg (determined in the chamber) in the ischemic solution, 
which represents a reasonably high level of hypoxia.  
2.7. Experimental protocols 
In the present study 4 principal sets of experiments were performed: cell viability 
measurements, NADH measurements, [Ca2+]i transient measurements and AP measurements. 
In order to reach maximal, but still selective inhibition of the exchanger, ORM-10103 has 
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been used in 10 μM dose. At this dose no apparent effect of the inhibitor on further ion 
transporters (except a small inhibition of IKr) could be observed (Jost et al.; 2013). 
1) Viability measurements: Two subsets of experiments were performed. The 
ischemia/reperfusion protocols were identical to the corresponding subsets of the AP 
measurements (native, untreated and ORM-10103 treated cardiomyocytes). Since in normoxic 
conditions cell survival was usually close to 100% for at least an hour, no separate time 
control ( TC) measurements were performed
2) NADH measurements. Since NADH is inherently fluorescent, no cells in this group had to 
be loaded with external dye. Cardiomyocytes in the first subgroup were utilized as time 
control and were superfused with oxygenated Tyrode solution throughout the experiment; no 
simulated ischemia was introduced. The second subgroup of cells was subjected to a full cycle 
of ischemia/reperfusion (see above). 
3) [Ca2+]i transient measurements. These measurements were performed in cardiomyocytes 
loaded with Fluo 4-AM.  Five subsets of experiments were performed. The first subset was 
used for time control; no ischemia/reperfusion (I/R) cycle was applied. In the second one 
(untreated) cells were subjected to a full cycle of ischemia/reperfusion. In the third one 
(ORM-10103) cells were pretreated with 10 μM of ORM-10103, the selective NCX inhibitor, 
at the end of the control period but prior to the ischemia/reperfusion cycle. The fourth and 
fifth subsets were similar to the second and third ones, with the exception that in order to 
substantially increase the driving force for reverse mode NCX activity these solutions also 
contained the Na+/K+-ATP-ase (NKA) inhibitor strophantidine (1 μM). 
4) AP measurements: Three subsets of experiments were performed. The protocols were 
identical to the corresponding subsets of the [Ca2+]i transient measurements (i.e. untreated, 
ORM-10103 treated and time control), but these measurements were performed using 
unloaded cardiomyocytes. 
2.8. Variabilities of APD90 ,APD25 and the [Ca2+]i transient  
The beat-to-beat variability of APD90, APD25, and CaT amplitude were calculated by 
the analysis of 50 consecutive action potentials or [Ca2+]i transients from the steady-state 
section of the experiment, via using the following formulas:  
BVR(ADP90) =  (APD90;i+1-APD90;i)/(nbeatsx2) 
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BVR(ADP25) =  (APD25;i+1-APD25;i)/(nbeatsx2) 
Since the uncorrected CaT amplitude largely depends on nonspecific variables (cell size, dye 
concentration and leakage) and this dependence would also be reflected in the variabilities, 
the simple formula used to calculate short term APD variabilities may not be suitable to 
properly characterize CaT variabilities. Therefore, we normalized the raw variability data to 
the mean CaT amplitude (CaTTC), calculated from the corresponding time control 
experiments, as follows: 
BVR(CaT) =  (CaT amplitude;i+1- CaT amplitude;i)/((nbeatsx2) x mean CaTTC amplitude) 
2.9. Materials 
All materials were purchased from Sigma (St. Louis, Mo, USA) except for Fluo 4-AM 
(Life Technologies). ORM-10103 was a gift from Orion Pharma (Espoo, Finland). 
2.10. Data processing and statistics 
Individual cardiomyocytes - even if selected from the same isolation - show great 
variability in size and volume. Consequently, at the end of the loading process their 
fluorescent dye content - even at identical [Ca2+]i - showed significant variations and this 
variability was fully reflected by the magnitude of the optical signals. Therefore, to avoid 
abnormally high standard deviations caused solely by the heterogeneity of the dye content, 
fluorescence values were normalized to the control period.  
In contrast to the “survival” data shown in Fig. 1, all single cell data presented in Fig.s
2-9 were obtained from living cardiomyocytes, surviving the ischemia/reperfusion protocol. 
Incomplete single cell measurements were discarded from data analysis. All values presented 
are arithmetic means ± S.E.M. All data were analyzed using Students t test for paired or 
unpaired data, as relevant. Differences were considered significant when P was less than 0.05. 
3. Results 
3.1 Effect of selective NCX inhibition on cardiomyocyte viability  
The results obtained from the “survival” experiments are summarized in Fig. 1. 
Representative microscope fields from a pair of experiments performed on untreated and 
ORM-10103 treated cardiomyocytes are shown in panels (A) and (B), respectively. For 
survival analysis regions of interest (ROIs, white circles) containing ~20 predominantly 
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intact, contracting cardiomyocytes were selected at the beginning of the normoxic period (left 
panels). Based on their morphological characteristics cells in the ROI were classified into two 
groups: Class A: elongated cells with intact border and clearly visible striation. Class B: dead 
cells, or cells on the verge of death with no visible striation and typically in full contracture. 
At the end of the ischemic period most cardiomyocytes in both ROIs seem to be principally 
intact (mid panels). At the end of the reperfusion period, however, a substantial number of the 
cells was in contracture (right panels). This is especially true for the untreated group. 
Mean values, determined for both groups in the last minute of the control (normoxic), 
ischemia and reperfusion periods, are summarized in panel (C). The distribution of cells in the 
normoxic state was close to identical in both groups, and the majority of these cells were 
intact (78% and 81% in the untreated and ORM-10103 treated groups, respectively). As noted 
above, ischemia by itself apparently did not influence cell distribution in either group. In 
contrast, reperfusion had a detrimental effect on the untreated group: 71% (112 out of 156) of 
the cells intact at the end of ischemia died during reperfusion. Application of 10 μM ORM-
10103 had a clearly protective effect on cell viability; significantly less, only 47% (76 out of 
161) of the ORM-treated cells died by the end of the reperfusion period.   
3.2. Validation of intracellular ischemia by monitoring NADH levels  
The onset and relative depth of intracellular ischemia were verified by monitoring 
ischemia induced shifts in inherent fluorescence of dye-unloaded (native) cardiomyocytes and 
comparing those to nonspecific, time dependent fluorescence shifts developed in nonischemic 
cells. In order to estimate the depth of intracellular ischemia NaCN – a well known inhibitor 
of the mitochondrial cytaa3, often used to induce close to maximal short term reduction in 
NAD+ - was applied immediately following the reperfusion period. The results of the NADH 
fluorescence measurements are shown in Fig. 2.  
In cells not exposed to ischemia (time control group) only a limited, gradual decrease 
in cellular fluorescence, most likely a consequence of nonspecific changes (bleaching), could 
be observed (black circles). In contrast, in cells exposed to the ischemia/reperfusion protocol 
cellular fluorescence increased significantly during the ischemic period (grey circles). When 
switching perfusion solutions ~30 s was necessary for the new perfusate to reach the chamber, 
and about further ~1 min to mix and decrease the oxygen level in the chamber low enough to 
induce anaerobic transition. Ischemia-induced NADH shifts were calculated by correcting raw 
fluorescence values for nonspecific changes (calculated from the time control measurements). 
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Furthermore, all fluorescence data shown in Fig. 2 were normalized to the level obtained from 
the same cell at the beginning of the normoxic period.  
In the early phase of ischemia a steep increase in [NADH] could be observed (8.4 ± 
0.4%; n = 6). During the ischemic cycle the level of the corrected fluorescence increase was 
varying, most probably reflecting the minor variations in oxygen levels inside the chamber. 
During reperfusion [NADH] gradually returned to control level, even a minimal, insignificant 
undershoot could be observed. Compared to simulated ischemia, the application of cyanate 
induced significantly larger NAD+ reduction (ischemic and time control cells: 12.2 ± 2.8% 
and 15.1 ± 1.9%, respectively, n = 4). During these measurements pO2 levels were repetitively 
determined using a blood gas analyzer (ABL 505, Radiometer, Denmark) in 50 μl samples 
collected from the central area of the chamber. While the pO2 level in the chamber was 
sufficiently high during normoxia (181.7 ± 7.5 mmHg, n = 25) under ischemic perfusion it 
was always lower than 40 mmHg (32.9 ± 1.6 mmHg, n = 25). 
3.3. The effect of selective NCX inhibition on the [Ca2+]i transient 
A set of representative CaT waveforms is shown in Fig.s 3-5. In time control 
measurements only a small, gradient decrease in the magnitude and baseline of the transient 
could be observed (Fig. 3A). This gradual decrease is predominantly a consequence of dye 
leakage/extrusion from the cell. Interestingly, in normoxic conditions the application of 10 
μM ORM-10103 had no apparent effect on the magnitude or kinetics of the transient (Fig.
3B). During simulated ischemia in both strophantidine untreated (Fig. 4A) and treated (Fig.
5A) cells significant changes in the magnitude and kinetics of the CaT could be observed. The 
traces shown in these panels were corrected for dye leakage (the rate of dye leakage/extrusion 
was approximated from time control recordings) and nonspecific background fluorescence 
(determined at the beginning and end of the recording, by removing the cell from the optical 
field), but – in contrast to all other (calculated) panels - were not normalized to the control 
traces. Compared to the normoxic waveforms (left traces), application of 10 μM ORM-10103 
did not prevent or revert most of these changes (mid traces), indeed, it induced further 
alterations in both the magnitude and kinetics of the transient. During reperfusion neither 
groups could completely recover, whether untreated, or treated with 1 μM strophantidine or 
10 μM ORM-10103 or both (right traces). 
Ischemia/reperfusion induced changes in characteristic parameters of the CaT in 
strophantidine-untreated cells are summarized in the panels B-E of Fig. 4. In this and a few 
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other Fig.s (Fig.s 5 and 8) two distinct significance levels were calculated and presented: 
hashmarks (#) and asterisks (*) indicate significant difference between untreated vs. time 
control, and ORM-treated vs. untreated values, respectively. Significant changes in the 
amplitude of the CaT in untreated compared to time control cells could only be observed 
during the early phase of ischemia (0.836 ± 0.03 vs. 0.979 ± 0.02; n=14) (B). In contrast, 10 
μM ORM-10103 caused a steady, gradual decrease in the amplitude of the CaT (0.76 ± 0.06 
vs. 0.38 ± 0.05; n=14), which became significant (compared to ORM-10103 untreated cells) 
during reperfusion. In the slope of the transient (C) ischemia induced a gradual, significant 
decrease in untreated cardiomyocytes compared to time control (0.55 ± 0.07 vs. 0.54 ± 0.05 
n=14) and ORM treatment had no apparent effect on this ecrease. On the other side, during 
reperfusion the slope in the two groups changed in opposite direction - recovered in untreated, 
further decreased in treated cells, the differences between the two groups became significant 
(0.67 ± 0.09 vs. 0.39 ± 0.04; n=14). In untreated cells ischemia also caused a significant 
increase in the half relaxation time (RT50) of the CaT, compared to time control (D). In these 
cells RT50 recovered during reperfusion, typically with a moderate undershoot compared to 
time control. In contrast, treatment with ORM-10103 significant decreased RT50 (0.90 ± 0.03 
vs. 0.79 ± 0.03; n=14) during late ischemia and reperfusion, compared to untreated cells. The 
largest modulatory effect of ORM-10103 treatment could be observed in [Ca2+]iD (E). As 
expected, ischemia induced a substantial raise in [Ca2+]iD, which became significant by the 2nd 
min of ischemia. Upon reperfusion [Ca2+]iD slowly normalized, however, during its early 
phase (~6 min) it was still significantly higher than in time control cells (1.04 ± 0.03 vs. 0.92 
± 0.02; n=14). Pretreatment of the cardiomyocytes with 10 μM ORM-10103 completely 
eliminated the raise in [Ca2+]iD and by the end of the ischemic period it even decreased below 
time control (0.73 ± 0.08 vs. 0.64 ± 0.06; n=14). During reperfusion [Ca2+]iD in these cells 
was permanently below control.  
Ischemia/reperfusion induced changes in characteristic parameters of the CaT in 
strophantidine treated cells are summarized in panels B-E of Fig. 5. In these cells no 
significant changes in the amplitude of the CaT could be observed during ischemia or 
reperfusion (B). Compared to time control, the slope of the CaT gradually, but significantly 
decreased during both ischemia and reperfusion (C). ORM-10103 failed to influence the 
ischemia induced fall in the slope of the CaT, but significantly limited its further decrease 
during reperfusion (0.55 ± 0.1 vs. 0.21 ± 0.02; n=6). In ORM-10103 untreated cells RT50 was 
close to the time control during both ischemia and reperfusion (D). In contrast, the application 
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of 10 μM ORM-10103 induced a significant decrease in this parameter during reperfusion 
(1.17 ± 0.11 vs. 0.81 ± 0.06; n=6). The already significant ischemia-induced elevation in 
[Ca2+]iD, observed in the untreated myocytes, was further significantly augmented in 
strophantidine treated cells (E) and this marked increase was apparently maintained during 
the entire period of reperfusion. Application of 10 μM ORM-10103 completely eliminated the 
hugh ischemia induced elevation in [Ca2+]iD; indeed, diastolic [Ca2+]i levels in these cells did 
not differ significantly from levels measured in normoxic cardiomyocytes (0.71 ± 0.06 vs. 
0.65± 0.06; n=6). 
The beneficial effect of ORM-10103 treatment during reperfusion became even more 
evident by comparing short term variabilities of the CaT amplitudes. Variabilities calculated 
from all four experimental groups for the normoxic, ischemic and reperfusion periods are 
summarized in Fig. 6. Representative Poincare plots, obtained in untreated, ORM-10103 
treated, strophantidine treated and strophantidine + ORM-10103 treated cells, are shown in 
panels A, B, C and D, respectively. Mean data from untreated and ORM-10103 treated cells 
are provided in panel (E). As one can conclude from these diagrams, in untreated cells no 
apparent ischemia/reperfusion induced changes in CaT variabilities could be observed, while 
ORM 10103 treatment caused a small, rather insignificant decrease in both cases (0,011 ± 
0.002 vs. 0.010 ± 0.001 and 0,012 ± 0.003 vs. 0.010 ± 0.001; n=6, during ischemia and 
reperfusion, respectively). In contrast, as shown in panel (F), during ischemia strophantidine 
significantly enhanced the short term variability (0.113 ± 0.037 vs. 0.037 ± 0.016; n=6) which 
was even further augmented during reperfusion (0,272,± 0,055. vs. 0,018 ± 0,009; n=6). This 
large elevation was, again, fully eliminated by the application of 10 μM ORM-10103.  
3.3. Effect of selective NCX inhibition on AP parameters 
Representative AP waveforms are shown in Fig. 7. During normoxia 10 μM ORM-
10103 evoked moderate APD shortening without substantially modulating either its amplitude 
or the resting membrane potential (A). During simulated ischemia, however, significant 
changes in the shape and kinetics of the APs developed and the resting membrane potential 
was depolarized (middle trace in panel B). Both parameters were apparently normalized 
during reperfusion (right trace in panel B). The AP shortening effect of 10 μM ORM-10103 
observed in normoxic cells was even more evident during both ischemia and reperfusion 
(panel C); however, no additional ORM-10103 induced shifts in AP could be observed. 
Indeed, the ORM-treatment failed to substantially reduce the ischemia induced depolarization 
of the resting membrane potential.
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Ischemia/reperfusion induced alterations in the characteristic parameters of the AP in 
untreated and ORM-10103 treated cardiomyocytes are summarized in Fig. 8. Compared to 
normoxic cells, ischemia induced a significant reduction in the amplitude, a substantial, but 
not significant decrease in the plateau level of the AP (A, B), and the resting membrane 
potential became significantly depolarized (C). These parameters were practically restored 
during reperfusion. ORM-10103 had no apparent effect on the magnitude of the ischemia 
induced shifts, neither on the recovery of these variables. 
In order to characterize major changes in AP kinetics APD25 (D) and APD90 (E) were 
determined and from these variables AP triangulation was calculated (F). Ischemia induced a 
moderate decrease in APD25 which was normalized during reperfusion. Compared to the 
untreated cells substantially larger decrease in APD25 could be observed in ORM-10103 
treated cardiomyocytes, became significant in the late phase of ischemia and did not recover 
during reperfusion (0.90 ± 0.09 vs. 0.66 ± 0.09; n=9). Qualitatively similar, but augmented 
ischemia induced shortening could be observed in APD90, however, the differences between 
the two groups were not significant during either ischemia or reperfusion. Compared to the 
time control cells, ischemia induced a large, significant decrease in AP triangulation in both 
groups, but again, the differences between the untreated and ORM-10103 treated groups were 
not significant (0.61 ± 0.07 vs. 0.76 ± 0.17; n=9). 
The effect of ORM-10103 treatment during ischemia/reperfusion on the characteristics 
of the AP was further analyzed by calculating short term variabilities in APD90 and APD25. 
Results of these calculations are summarized in Fig. 9. Representative Poincare plots taken 
from untreated and ORM-10103 treated cardiomyocytes are presented in panels (A-D). The 
average values obtained in the APD90 and APD25 groups are shown in panels (E) and (F),
respectively. Under normoxic conditions APD variabilities were similar in both groups. 
Ischemia induced moderate, but insignificant decrease in APD90 variabilities in the untreated 
group, while there was no apparent change in the ORM-10103 treated group. In contrast, 
APD25 variabilities failed to change in the control group, but showed a tendency to decrease 
following ORM-10103 treatment. During reperfusion the only significant change was an 
elevation in APD90 variabilities determined in the untreated group. ORM-10103 treatment 
eliminated this increase (5.37 ± 0.96 vs. 3.47 ± 0.69 ms; n=9). 
 
 
 14
 
4. Discussion 
Since the Na+/Ca2+ exchanger plays a crucial role in maintaining [Ca2+]i homeostasis, 
any abnormal shift in its transport rate or direction exerts a significant impact on cardiac 
contractile function and electrical activity. Its augmented reverse mode transport induces 
[Ca2+]i overload (e.g. during ischemia/reperfusion) and its increased forward mode activity 
leads to gradual [Ca2+]i loss (e.g. in chronic heart failure) (Allen and Orchard, 1987; Diaz and 
Wilson, 2006; Frohlich et al.; 2013). In both pathological conditions partial NCX inhibition 
may normalize the delicate balance in intracellular Ca2+ handling, resulting in effective 
protection against the progression of the disease. A number of previous studies provided 
important information on the consequences of NCX inhibition in healthy and diseased hearts 
(Inserte et al., 2002; MacDonald and Howlett, 2008), however, correct interpretation of these 
results was seriously hampered by the lack of selectivity of the used inhibitors. Therefore, in 
the present study we evaluated the efficacy of a new, selective NCX inhibitor, ORM-10103 
(Jost et al.; 2013) to protect canine ventricular cardiomyocytes during simulated 
ischemia/reperfusion. 
4.1 Cell viability 
A most direct way to test the efficacy of the selective NCX blockade in protecting 
cardiomyocytes against ischemia/reperfusion injuries is to compare cell survival between 
untreated and treated groups (Fig. 1). Instead of using vital dyes, we followed a similarly 
effective classification, based simply on the shape and visibility of the striation of the cell 
(Maddaford et al., 1999). This form of classification may also have some benefits since with 
proper experience one is able to reliably dissect crippled, dying cardiomyocytes from safely 
surviving cells. The results of these experiments are straightforward and seem to support the 
hypothesis that partial, selective NCX inhibition by ORM-10103 may effectively protect the 
cardiomyocytes from severe ischemia/reperfusion induced injuries. This protection is most 
probably a direct consequence of the NCX inhibitory effect on the buildup of ischemia-
induced Ca2+i overload leading to contracture and elevated [Ca2+]iD, which may severely 
compromise mitochondrial function (Eisner et al., 2005). A further contribution of ORM-
10103 to cardiomyocyte survival may be its significant stabilizing effect on the CaT and APD 
by inhibiting the ischemic increase in their variabilities (Diaz et al., 2004).  
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4.2. Level of ischemia 
During ischemia compromised oxidative metabolism leads to marked reduction in 
mitochondrial NAD+ content, reflected in increased cellular fluorescence. Maximal short term 
raise in [NADH]m can be well approximated following cyanate application. The ratio of the 
magnitudes of fluorescence increase during ischemia and cyanate treatment is characteristic of 
the level of cellular ischemia. In this study the increase in cellular fluorescence during 
simulated ischemia was found to be substantially less than in the presence of cyanate (Fig. 2). 
Consequently, during this protocol oxidative metabolism was severely compromised, but not 
abolished (Lu et al., 2005). This is not surprising, since the oxygen level in the chamber was 
low, but not zero (32.9 ± 1.6 mmHg).  Therefore, the simulated ischemia protocol is more 
suitable to model the lateral, low-flow zone than the central now-flow region of the infarcted 
area. As shown in Fig. 2 NADH fluorescence was above time control during the ischemic 
period and only returned to control level during reperfusion. The apparent gradual 
fluorescence decrease during the ischemic period was probably not caused by bleaching only, 
since the rate of bleaching, estimated from the time control measurements, was substantially 
lower. Indeed, the bleaching-independent component of the decrease could originate from two 
principal sources. First, the pO2 level, reached in the chamber, was probably very close to the 
critical pO2 for isolated, active cardiomyocytes; consequently, even a small shift in chamber 
pO2 could induce a marked shift in [NADH]. Another reason may be that in the absence of 
glucose the substrate availability during ischemia is decreasing, leading to partial reoxidation 
of the mitochondrial NADH pool. At this moment we have no specific data to settle this issue; 
both explanations are feasible and even may act simultaneously (Eng et al., 1989). 
4.3. [Ca2+]i transient  
In the ORM-untreated cells all well known characteristic consequences of ischemia 
induced [Ca2+]i accumulation could be observed (Fig. 3). Diastolic [Ca2+]i rose (E) and since 
the amplitude of the CaT did not decrease simultaneously (B), systolic [Ca2+]i increased, as 
well.. The kinetic parameters CaT were also altered. The ON slope of the CaT was reduced 
(C); the half relaxation time (RT50) increased (D).  
The background of these effects is highly complex: reduced SERCA activity following 
ATP depletion leads to decreased SR Ca2+ content (see the reduced slope and amplitude of the 
CaT); the depolarization in resting membrane potential decreases the forward, the high [Na+]i 
increases the reverse activity of the NCX. The latter also facilitates Ca2+ influx, considerably 
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increasing the amount of [Ca2+]i to be extruded (Bers, 2008; Lee and Allen, 1992). Reduced 
SERCA and forward NCX activities should lead to simultaneously decreased [Ca2+]SR and 
elevated [Ca2+]i. Upon reperfusion the amplitude and slope of the CaT and (slowly) [Ca2+]iD
were restored (O'Brien et al., 2008). In contrast, RT50 was shortened. The acceleration of CaT 
relaxation during reperfusion may be related to the fast recovery of the [K+]i and subsequent 
membrane repolarization, which, in turn, may significantly increase the efficacy of the 
forward NCX activity and facilitate the simultaneous recovery of the [ATP], subsequently 
normalizing SERCA activity. The reduction of RT50 below control level may reflect an 
“overshoot” in Ca2+ handling during recovery (Talukder et al., 2009). 
Application of ORM-10103 had a significant impact on ischemia/reperfusion induced 
CaT alterations. The amplitude and slope of the CaT were gradually decreased, although these 
differences only became significant during reperfusion. The large decrease observed in the 
amplitude of the CaT may support the notion that during ischemia NCX mediated beat-to-beat 
Ca2+ influx has an important role in compensating reduced [Ca2+]SR. More importantly, the 
significant ischemia induced raise in [Ca2+]iD and RT50 were fully blocked by ORM-10103. 
During reperfusion these parameters significantly further decreased, directly supporting the 
hypothesis that the predominant effect of NCX blockade during ischemia/reperfusion is an 
effective suppression of the Na+i-accumulation induced activation of the reverse mode NCX 
activity (Wei et al., 2007).  
Further support of this conclusion was provided from the strophantidine experiments. 
By inhibition of the Na+/K+ ATP-ase strophantidine facilitates Na+i accumulation and 
consequently, prolongs reverse NCX activity. Indeed, ischemia-induced [Ca2+]iD raise was 
approximately doubled, and, in contrast to the untreated cells, even further increased during 
reperfusion. ORM-10103 effectively and completely blocked this raise (Fig. 4E).  
Another, highly promising protective effect of ORM-10103 is demonstrated in Fig. 5. 
In strophantidine-untreated cardiomyocytes the variability of CaT was limited, suggesting 
partially maintained feedback control of the Ca2+ release on transsarcolemmal Ca2+ fluxes. In 
these cells ORM-10103 had no significant effect on variability. In contrast, in strophantidine-
treated cardiomyocytes CaT variabilities during ischemia and especially during reperfusion 
were substantially augmented, suggesting that the delicate balance between the trigger and the 
feed-back systems was severely disturbed, leading to large fluctuations in beat-to-beat Ca2+ 
release and substantial instability of the Ca-handling (Eisner et al., 2005). This raise was 
completely diminished by application of ORM-10103, which effect may be contributed to the 
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marked reduction in [Ca2+]i. Since elevated CaT variability is often considered as a sensitive 
cellular marker for increased arrhythmia propensity (Tokuno et al., 2000), a reasonable 
conclusion of these results is that ORM-10103 is likely to substantially decrease the incidence 
of ischemia/reperfusion induced triggered cardiac arrhythmias. 
4.4. AP morphology 
Ischemia/reperfusion induced arrhythmias are usually generated by two interdependent 
intracellular mechanisms: [Ca2+]i overload (MacDonald and Howlett, 2008) and sarcolemma 
depolarization (MacDonald and Howlett, 2008). [Ca2+]i overload induces increased leakage of 
the [Ca2+]SR, enhancing the probabilities of diastolic Ca2+ releases (Wei et al., 2007). The 
subsequent inward current (mainly via forward INCX) facilitates the onset of Ca2+-dependent, 
potentially lethal ventricular arrhythmias (Nagy et al., 2004). During ischemia APD is 
significantly shortened. Membrane depolarization via elevated K+i efflux reduces the activity 
of the Na+ and Ca2+ channels and attenuates Ca2+ extrusion (Lukas and Antzelevitch, 1993). 
In contrast, augmented [Ca2+]iD facilitates Ca2+ efflux via forward INCX activity. Finally, ATP 
depletion-activated IK(ATP) carries extra repolarizing current. The resulting redistribution of the 
Ca2+ and repolarizing K+ fluxes may substantially contribute to increased short-term APD90 
and CaT variabilities during reperfusion. 
In normoxic cells ORM-10103 treatment induced moderate APD shortening (Fig. 6A) 
probably via inhibition of the forward INCX. Further changes in AP were not observed. During 
ischemia the sarcolemma depolarized (Fig. 6B) and the spike potential diminished, however, 
both parameters recovered during reperfusion. ORM-10103 treatment failed to protect the 
cardiomyocytes against ischemia-induced AP perturbations (Fig. 6C). The apparent failure of 
ORM-10103 to counteract ischemic AP changes is even more obvious in Fig. 7. The 
depressed AP amplitude (A) and plateau (B), increased triangulation (F) and substantial 
depolarization of the resting potential (C) were practically uninfluenced by ORM-10103 
treatment. Indeed, the ischemia-induced APD shortening was even augmented (D-E). The 
reason for the inefficacy of ORM-10103 to prevent these arrhythmogenic disturbances in AP 
may be complex. Though [Ca2+]i changes are important modulators of the AP (Louch et al., 
2002), it is more dependent on the balance of the inward Na+, Ca2+ and outward K+ currents. 
Except for a minimal decrease in the fast component of the delayed rectifier potassium current 
(IKr) neither of these factors are affected by ORM-10103 (Jost et al., 2013). This may be the 
primary cause for the minimal sensitivity of the AP to selective NCX blockade. 
 18
The only apparent beneficial effect of ORM-10103 on variables of the action potential 
was a significant  reduction in reperfusion-induced raise of APD90 variabilities (Fig. 8). This 
may be a consequence of the increased stability of Ca2+-handling and is most probably a 
consequence of the decreased [Ca2+]i overload and reduced [Ca2+]iD (Wei et al., 2007).  
4.5. Limitations 
It must be emphasized, that the data provided in Fig. 1 principally differ from data 
presented in Fig.s 2-9. “Survival” experiments were performed on full cell populations (the 
only criterion when selecting the ROI at the beginning of the experiments was to find an area 
with predominantly healthy, contracting cells). Our present data shown in Fig. 1 and data in 
the literature (Moens et al., 2005) clearly demonstrate that a significant fraction of the 
cardiomyocytes does not survive the simulated ischemia protocol and dies during the 
reperfusion period. Since incomplete measurements were discarded from further proccessing, 
all single cell (NADH, CaT, AP) data presented were obtained from a limited cellular pool – 
i.e. surviving cells. 
5. Conclusion 
A major conclusion of the present study is that ORM-10103 treatment proved to be 
highly effective against ischemia/reperfusion induced arrhythmogenic shifts in [Ca2+]i 
homeostasis by limiting the [Ca2+]i overload and eliminating the ischemia-induced raise in 
diastolic [Ca2+]i. This beneficial effect may primarily be contributed to the inhibition of the 
significantly enhanced reverse mode activity of the Na+/Ca2+ exchanger, activated by the 
increased [Na+]i. Furthermore, ORM-10103 seems to restore the markedly weakened 
reperfusion-induced stability of the [Ca2+]i transient and significantly facilitates the post-
reperfusion survival of the cardiomyocytes. However, in certain pathological conditions the 
efficacy of its protective effect may be hampered by its apparent inability to protect the heart 
against the arrhythmogenic disturbances in AP morphology. 
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Fig. legends 
Fig. 1.   Effect of 10 µM ORM-10103 on cardiomyocyte viability 
(A) and (B) Representative selected microscope fields from a pair of experiments 
performed on untreated and ORM-10103 treated native cardiomyocytes. Still images 
were periodically captured using a digital photo camera. Classification of the cells 
was based on morphological variables: Class A: cells with normal, elongated shape, 
intact border and visible striation; Class B: cells dead or at the verge of death, in 
severe contracture, without apparent striation. (C) Mean values prior to (3rd min), 
during (15th min) and following (26th min) simulated ischemia. The asterisks indicate 
significant (P<0.05) difference between individual untreated and ORM-10103 
treated values. 
 
Fig. 2. Effect of simulated ischemia/reperfusion on NADH levels in isolated dye-free 
cardiomyocytes. In untreated, native cardiomyocytes NADH was excited at 360 nm, 
native fluorescence during the ischemia/reperfusion protocol has been monitored at 
450 nm (grey circles). Nonspecific fluorescence shifts, caused by NADH bleaching, 
were estimated from normoxic (time control) cardiomyocytes (black circles). At the 
end of the protocols 10mM sodium-cyanate (NaCN) was applied to induce maximal 
NADH reduction (squares). Asterisks indicate significant (P<0.05) difference 
between individual ischemic and time control values (n=6)  
 
Fig. 3. Representative [Ca2+]i transients recorded from untreated normoxic (time control) 
and ORM-10103 treated normoxic cardiomyocytes. In CaT measurements the 
cardiomyocytes were loaded with a Ca2+-sensitive fluorescent dye, Fluo 4-AM. (A)
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Time control (normoxic) measurements were performed to enable the estimation of 
the rate of nonspecific fluorescence decay caused by dye leakage/extrusion. This 
decay factor was used to correct raw data obtained from all ischemia/reperfusion 
experiments. (B) In a predominant number of normoxic cardiomyocytes application 
of 10 μM ORM-10103 did not cause apparent changes in the magnitude, shape and 
decay kinetics of the transient, while in a minority of cells some decrease could be 
observed.  
 
Fig. 4. Changes in major CaT parameters during simulated ischemia/reperfusion and the 
effect of 10 µM ORM-10103 treatment on these parameters in strophantidine-
untreated cardiomyocytes. (A) Representative raw recordings of CaT from untreated 
(upper traces) and ORM-treated (lower traces) cells prior to, during and following 
simulated ischemia. CaTs shown in this panel were corrected for dye leakage and 
nonspecific background, but were not normalized. (B-E) Ischemia/reperfusion 
induced shifts in major CaT variables and the effect of 10 μM ORM-10103 on the 
(B) magnitude, (C) slope and (D) half relaxation time of the transients. Parameter 
values were obtained in the 3rd min (control), 6th, 10th, and 15th min (early, mid and 
late phase of ischemia), and 26th and 30th min (early and late phase of reperfusion) of 
the recordings. (E) The changes in [Ca2+]iD levels are shown in more details. Since 
the absolute level of the dye fluorescence depends on the size of the individual cells, 
as well, as their actual dye concentration, all experiments were self controlled and all 
fluorescence values obtained during ischemia/reperfusion were normalized to the 
mean of the control values determined from the same cell for each minute during the 
normoxic period. (C) Slope values, calculated from the CaTs by fitting a line to the 
ON slope at its maximal increase rate (i.e. at the peak of the first derivative). 
Fluorescence data were analyzed using Students t test for paired or unpaired data, as 
relevant. Hash marks and asterisks indicate significant (P<0.05) difference between 
individual time control vs. untreated and untreated vs. ORM-treated values, 
respectively. Since two of the three graphs depicted in these panels are often in close 
proximity, the commonly used placement of the significance marks (i.e. on top of 
the corresponding graphs) in these panels could be misleading. Therefore, both 
significance marks are shown in a separate bar on top of the panel. 
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Fig. 5. Changes in major CaT parameters during simulated ischemia/reperfusion and the 
effect of 10 µM ORM-10103 treatment on these parameters in strophantidine-
treated cardiomyocytes. (A) Representative raw recordings of CaT from untreated 
(upper traces) and ORM-treated (lower traces) cells prior to, during and following 
simulated ischemia. (B-E) Ischemia/reperfusion induced shifts in major CaT 
variables and the effect of 10 μM ORM-10103 on the (B) magnitude, (C) slope and 
(D) half relaxation time of the transients, and (E) [Ca2+]iD levels. All calculations 
and representations were performed like in Fig. 4.  
 
Fig. 6. The effect of 10µM ORM-10103 on the amplitude variability of the [Ca2+]i transient. 
Variabilities in the amplitude of the CaT were calculated from all four sets of 
experiments. Representative examples from untreated, ORM-treated, strophantidine-
treated and strophantidine+ORM-treated are presented in panels (A), (B), (C) and 
(D), respectively. Summarized variabilities for the strophantidine-untreated and 
treated cardiomyocytes are shown in panels (E) and (F), respectively. The asterisk 
indicate significant (P<0.05) difference between individual untreated and ORM-
treated values.  
 
Fig. 7. Representative traces from the action potential measurements. AP measurements 
were performed in native (dye-unloaded) cells. (A) The effect of 10 μM ORM-
10103 on normoxic cardiomyocytes. (B) and (C) The effect of the simulated 
ischemia/reperfusion protocol on action potentials recorded ORM-10103-untreated 
and treated cardiomyocytes, respectively. 
 
Fig. 8. Changes in major AP parameters during simulated ischemia/reperfusion and the 
effect of 10µM ORM-10103 treatment on these parameters in strophantidine-
untreated cardiomyocytes. (A) amplitude; (B) plateau level; (C) resting membrane 
potential; (D) APD25; (E) APD90; and (F) triangulation. Parameter values were 
obtained in the 3rd min (control), 6th, 10th and 15th min (early, mid and late phase of 
ischemia), and 26th and 30th min (early and late phase of reperfusion) of the 
recordings. All data, except the resting membrane potential values, were normalized 
to the  normoxic (control) period and analyzed using Students t test for paired or 
unpaired data, as relevant. Hash marks and asterisks indicate significant (p<0.05) 
difference between individual time control vs. untreated and untreated vs. ORM-
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treated values, respectively. All significance marks are shown in a separate bar on 
top of the corresponding panel. 
 
Fig. 9. The effect of 10 µM ORM-10103 on APD90 and APD25 variabilities 
 (A-B) and (C-D) Representative examples for calculated APD90 and APD25 
variabilities determined from untreated and ORM-treated cardiomyocytes, 
respectively. (E) Summarized APD90 and (F) APD25 variabilities. The asterisk 
indicates significant (P<0.05) difference between individual untreated and ORM-
treated values. 
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